Daxor (DXR) CMO boosts stake with 5,941-share equity grant

Rhea-AI Filing Summary

Jefferies John reported open-market purchase transactions in this Form 4 filing.

DAXOR CORP Chief Medical Officer John Jefferies acquired additional equity in the company through stock grants. He received 5,941 shares of Daxor Common Stock as compensation, including 3,656 shares that will vest on March 20, 2029 and 2,285 shares that vested on March 20, 2026. After these transactions, he directly holds 23,557 shares of Daxor Common Stock.

Insider Trade Summary

2 transactions reported

Net Buy 2 txns

Insider Jefferies John

Role Chief Medical Officer

Bought 5,941 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Daxor Common Stock	3,656	$0.00	--
Purchase	Daxor Common Stock	2,285	$0.00	--

Holdings After Transaction: Daxor Common Stock — 21,272 shares (Direct)

Footnotes (1)

1. 3,656 shares granted vest on March 20, 2029. 2,285 shares granted vested on March 20, 2026

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jefferies John

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE TENNESSEE 37830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Daxor Common Stock	03/20/2026		P		3,656(1)	A	$0	21,272	D
Daxor Common Stock	03/20/2026		P		2,285(2)	A	$0	23,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 3,656 shares granted vest on March 20, 2029.

2. 2,285 shares granted vested on March 20, 2026

	/s/ John Jefferies	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did DAXOR CORP (DXR) Chief Medical Officer report in this Form 4?

The Chief Medical Officer, John Jefferies, reported acquiring 5,941 Daxor Common Stock shares as equity compensation. These were recorded as grants and vesting events rather than cash purchases, increasing his direct ownership position.

How many DAXOR CORP (DXR) shares did John Jefferies acquire?

John Jefferies acquired 5,941 shares of Daxor Common Stock. This total comes from two grants: 3,656 shares scheduled to vest in 2029 and 2,285 shares that vested in 2026, all recorded in this insider filing.

What are the vesting terms of the new DAXOR CORP (DXR) share grants?

One grant covers 3,656 shares that will vest on March 20, 2029. Another 2,285-share grant is reported as having vested on March 20, 2026, indicating both future and already-vested compensation components in this filing.

What is John Jefferies’ total DAXOR CORP (DXR) share ownership after these grants?

Following these compensation-related share grants, John Jefferies directly owns 23,557 shares of Daxor Common Stock. This figure, reported in the Form 4, reflects his updated post-transaction ownership position in the company.

Were the DAXOR CORP (DXR) transactions open-market buys or equity grants?

Although coded as purchases, footnotes describe the 3,656 and 2,285 share entries as shares granted and vesting. This indicates they are equity compensation grants and vesting events, not cash-funded open-market stock purchases.